Home/Tag: CIRM

Late-Stage Preclinical Research Targeting Prostate Cancer Gets Almost $4 Million Support from California’s Stem Cell Agency

A program hoping to supercharge a patient’s own immune system cells to attack and kill a treatment resistant form of prostate cancer was today awarded $3.99 million by the governing Board of the California Institute for Regenerative Medicine (CIRM) In the U.S., prostate cancer is the second most common cause of cancer deaths in men. 

July 23rd, 2018|Categories: Cancer, Disease Specific|Tags: , , , |

CIRM-Funded Clinical Trial for ALS Given Go Ahead to Treat Patients

October 24, 2016 Oakland, CA – An ingenious method that uses a patient as their own control has been given clearance to start a clinical trial to treat amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s Disease. The California Institute for Regenerative Medicine (CIRM) is funding the trial. ALS is a devastating disease that

October 24th, 2016|Categories: ALS, Clinical Trials|Tags: , , |

Stem Cell Agency Spinal Cord Injury Clinical Trial Passes Safety Hurdles

Posted: August 31, 2016 Oakland, CA – A clinical trial using stem cells to treat people with recent spinal cord injuries has cleared two key safety hurdles, and been given approval to expand the therapy to a larger group of patients with a much higher dose of cells. Asterias Biotherapeutics announced that its Data Monitoring

National honor for helping “the blind see”

JANUARY 7, 2016 / KEVIN MCCORMACK, CIRM blog Those of us fortunate to have good health take so many things for granted, not the least of which is our ability to see. But, according to the World Health Organization, there are 39 million people worldwide who are blind, and another 246 million who are visually

As CIRM opens world’s largest stem cell bank, scientists ready their research

Sep 1, 2015 A $32 million public-private bank — where California researchers collect stem cells and scientists from around the world can make withdrawals — officially opened Tuesday with the aim of accelerating the use of engineered stem cells to tackle a wide range of diseases. The bank, funded by the California Institute for Regenerative

Stem Cell Agency Funded Therapy for Blinding Disease Treats First Patients

August 11, 2015 San Francisco, CA – A clinical trial using stem cells to treat people who have lost their vision due to retinitis pigmentosa (RP) has treated its first four patients. CIRM, California’s stem cell agency, is funding the trial, which has FDA consent. “We are delighted to be moving into the clinic after

City of Hope Launches Stem Cell Therapy Clinic to Fight Incurable Disease in New Ways

March 23, 2015 11:30 AM Eastern Daylight Time DUARTE, Calif.--(BUSINESS WIRE)--In the field of cancer, patients have had surgery, chemotherapy and radiation therapy as options. Now, as City of Hope officially opens the Alpha Clinic for Cell Therapy and Innovation, patients battling cancer and other life-threatening diseases have another option: stem cell-based therapy. “We are

Stem cell trial for spinal cord injuries cleared by FDA

San Francisco Business Times, by Ron Leuty ~ August 27, 2014 An experimental treatment using controversial embryonic stem cells to fix severe spinal cord injuries has new life under a new company. Asterias Biotherapeutics Inc. of Menlo Park received Food and Drug Administration clearance Wednesday to go forward with a 13-person safety study of so-called

Stem Cell Agency’s Board Approves $70 Million Plan to Develop Innovative Alpha Clinics

July 25, 2013 San Francisco, CA – A $70 million plan to create a new statewide network of sites that will act as a hub for stem cell clinical trials was approved by the governing Board of California’s stem cell agency, the California Institute for Regenerative Medicine (CIRM). The goal of the Alpha Stem Cell

JDRF and California Institute for Regenerative Medicine Increase Funding of ViaCyte

NEW YORK and SAN FRANCISCO, Feb. 13, 2013 /PRNewswire via COMTEX/ -- Treatment being developed would use encapsulation to protect new insulin-producing cells derived from a stem cell precursor -- JDRF, the world's largest non-profit supporter of type 1 diabetes (T1D) research, and the California Institute for Regenerative Medicine (CIRM), California's stem cell agency, announced